Financial Statements

AnaptysBio Inc.

AnaptysBio Inc. (ANAB)


Balance Sheet Statement

Download ANAB income statement Download ANAB income statement
Year 2015201620172018
Cash and cash equivalents 51.7451.2981.25113.66
Short-term investments --167.22313.49
Cash and short-term investments 51.7451.29248.47427.14
Receivables 1.231.23--
Inventories ----
Property, Plant & Equipment Net 0.550.470.671.45
Goodwill and Intangible Assets ----
Long-term investments --75.9073.13
Tax assets -4.121.600.17
Total non-current assets 84.0894.727.690.80
Total current assets 2.823.9776.6774.78
Total assets 56.2862.18329.36509.00
Payables 1.522.282.325.44
Short-term debt --6.887.57
Total current liabilities 7.385.7114.0921.84
Long-term debt 4.9013.817.55-
Total debt 4.9013.8114.437.57
Deferred revenue 2.94---
Tax Liabilities 0.14---
Deposit Liabilities ----
Total non-current liabilities 84.0894.727.690.80
Total liabilities 91.46100.4321.7822.63
Other comprehensive income ---0.43-0.22
Retained earnings (deficit) -50.66-54.92-85.03-146.69
Total shareholders equity -35.18-38.25307.58486.37
Investments --243.12386.61
Net Debt -46.84-37.48-234.04-419.57
Other Assets 0.495.694.237.07
Other Liabilities 5.863.434.898.82

AnaptysBio Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes AnaptysBio Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.